MarketLens
Sign Up

Korro Bio: Why Director Sales Temper a 'Strong Buy' Consensus

3 months ago
SHARE THIS ON:

Korro Bio: Why Director Sales Temper a 'Strong Buy' Consensus

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 months ago

Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification

Kardigan holds $660.7M in liquid assets, funding 2–3 years of runway for three precision cardiology programs targeting genetic DCM, moderate CAVS, and post-hospitalization ASH. Pivotal 2027 readouts w...
Stock News•1 months ago

Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?

Keros Therapeutics' stock faces a cautious outlook as its rinvatercept pipeline offers upside but zero quarterly revenue, clinical risk, and a premium valuation weigh on the shares.
Stock News•2 months ago

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

Korro Bio (KRRO) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The upgrade could drive the stock higher in the near term.

Breaking News

View All →

Top Headlines

View More →
Stock News•49 minutes ago

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Alphabet Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GOOGL, GOOG

Stock News•1 hour ago

Prediction: Alphabet Will Soar After Oct. 28

Stock News•1 hour ago

Alphabet (GOOGL) Falls More Steeply Than Broader Market: What Investors Need to Know

Stock News•1 hour ago

Why Alphabet Inc. (GOOG) Dipped More Than Broader Market Today

Stock News•2 hours ago

OpenAI claims ex-employee brought confidential docs about ‘unreleased device' to Apple